Kiniksa Pharmaceuticals International Plc (KNSA): Next-Year EPS Estimate 36.47%
As of 2026-11-06, Kiniksa Pharmaceuticals International Plc (KNSA) has a next-year EPS growth estimate of 36.47%. Featured in 4 EPS revision reports, most recently on 2026-07-31.
On 2026-11-02, analyst consensus for KNSA's next-year EPS growth shifted from 39.86% to 36.47% — a negative change of 3.39 percentage points. The revised estimate has been sustained across 5 subsequent trading sessions. Current-year growth is projected at 97.88%.
What's Driving This
KNSA stock has been rising primarily because analysts raised the next-year EPS growth estimate to 39.98% from 34.48% on October 28, a 5.50 percentage-point revision, with
Generated 2026-11-06 from news as of 2026-11-06
Current Snapshot
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- EPS growth next year
- 36.47%
- EPS growth this year
- 97.88%
- EPS next quarter (est)
- $0.25
- Last price
- $88.34
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-11-06 | 36.47% | 97.88% | $0.25 | $88.34 |
| 2026-11-05 | 36.47% | 97.88% | $0.25 | $88.34 |
| 2026-11-04 | 36.47% | 97.88% | $0.25 | $96.12 |
| 2026-11-03 | 36.47% | 97.88% | $0.25 | $93.29 |
| 2026-11-02 | 36.47% | 97.88% | $0.25 | $90.80 |
| 2026-10-31 | 39.86% | 94.82% | $0.23 | $92.24 |
| 2026-10-30 | 39.86% | 94.82% | $0.23 | $92.24 |
| 2026-10-29 | 39.98% | 93.63% | $0.25 | $97.56 |
| 2026-10-28 | 39.98% | 93.63% | $0.25 | $95.18 |
| 2026-10-27 | 34.48% | 88.85% | $0.31 | $89.20 |
| 2026-10-26 | 47.79% | 83.04% | $0.37 | $72.98 |
| 2026-10-23 | 47.79% | 83.04% | $0.37 | $76.73 |
| 2026-10-22 | 48.14% | 82.04% | $0.37 | $80.79 |
| 2026-10-21 | 48.14% | 82.04% | $0.37 | $79.70 |
| 2026-10-20 | 48.14% | 82.04% | $0.37 | $83.17 |
| 2026-10-19 | 48.14% | 82.04% | $0.37 | $79.48 |
| 2026-10-16 | 48.14% | 82.04% | $0.37 | $78.59 |
| 2026-10-15 | 48.14% | 82.04% | $0.37 | $79.94 |
| 2026-10-14 | 47.30% | 85.70% | $0.37 | $78.84 |
| 2026-10-13 | 47.30% | 85.70% | $0.37 | $78.53 |
| 2026-10-12 | 47.30% | 85.70% | $0.37 | $79.24 |
| 2026-10-11 | 47.30% | 85.70% | $0.37 | $79.78 |
| 2026-10-10 | 47.30% | 85.70% | $0.37 | $79.78 |
| 2026-10-09 | 47.30% | 85.70% | $0.37 | $79.78 |
| 2026-10-08 | 47.30% | 85.70% | $0.37 | $78.75 |
| 2026-10-07 | 47.30% | 85.70% | $0.37 | $77.96 |
| 2026-10-06 | 47.30% | 85.70% | $0.37 | $77.09 |
| 2026-10-05 | 47.30% | 85.70% | $0.37 | $76.31 |
| 2026-10-04 | 47.30% | 85.70% | $0.37 | $75.79 |
| 2026-10-03 | 47.30% | 85.70% | $0.37 | $75.79 |
Reports Featuring KNSA
- 2026-07-31
NDLS +30.7% Leads EPS Revision Gainers; FFAI +28.1% Follows
- 2026-07-30
PMN Jumps 27.3% on EPS Revision and Alzheimer's Trial Data; KNSA, NDLS Follow
- 2026-07-29
KNSA Surges 28% on EPS Revision, Record Revenue; AMC, BZUN, CLF Also Climb
- 2026-07-28
CLF Surges 33.4% After EPS Revision; Steel Sector Leads
Recent News
- Kiniksa Crushes Estimates As ARCALYST Crosses $1 Billion Run-Rate, But Guidance Implies A Costlier, Slower Q4Earnings Whispers
- Kiniksa Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Portfolio ExecutionGlobeNewswire
- Kiniksa's Raised Outlook Implies A Bigger Third Quarter Than Wall Street Is ModelingEarnings Whispers
- Kiniksa Pharmaceuticals to Report Third Quarter 2026 Financial Results on October 27, 2026GlobeNewswire
- Dow Jones Futures Rise As SpaceX, Supermicro Revive AI Stocks; Tesla, Meta On DeckInvestor's Business Daily
- Biotech Stocks To Watch: Regeneron Partner Has Breakout In SightInvestor's Business Daily
- Kiniksa Pharmaceuticals, Ltd. Q2 2026 Earnings Call SummaryMoby
- Kiniksa Reports Strong Q2 Results, Raises 2026 ARCALYST Sales GuidanceInvestorsHub
- Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio ExecutionGlobeNewswire
- Kiniksa Pharmaceuticals to Report Second Quarter 2026 Financial Results on July 28, 2026GlobeNewswire
Screen Performance
Aggregate stats across all 2130 tickers our top-EPS-revision screen has flagged over the past 219 days.
- Median return since detection
- -3.9%
- % of tickers in the green
- 41%
- Median return on winners
- +23.3%
- Large revisions captured
- 2083
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
What is Kiniksa Pharmaceuticals International Plc's next-year EPS growth estimate?▾
As of 2026-11-06, Kiniksa Pharmaceuticals International Plc (KNSA) has a next-year EPS growth estimate of 36.47%, based on analyst consensus.
When was the latest EPS estimate revision for KNSA?▾
The most recent revision occurred on 2026-11-02, when analysts adjusted the next-year EPS growth estimate from 39.86% to 36.47%.
What sector and industry does Kiniksa Pharmaceuticals International Plc belong to?▾
Kiniksa Pharmaceuticals International Plc operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. KNSA appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Kiniksa Pharmaceuticals International Plc (KNSA) appears here because it was detected by our daily top-EPS-revision-performer screen.